DATAMEDS AI INC
MEDSNASDAQ🏆 #5010 by market capUS Equity
$3.64▼ $0.09 (−2.54%)
After hours · at closeTrack MEDS
Get earnings, price moves & breaking news on Telegram
24h▼ 2.5%
7d▼ 14.6%
14d▲ 124.7%
30d▲ 264.1%
ytd▼ 81.1%
1y▼ 92.4%
🏦Market Cap
$10M
Small Cap
📈Revenue Growth (YoY)
+28.7%
High Growth
📊Gross Margin
-125.1%
Thin
💵FCF Margin
-169.3%
Thin
⚖️P/S Ratio
1.2x
Cheap
Otter Score
56
Weak
Trading Snapshot
- Day Range
- $3.60 – $3.70
- 52-Week Range
- $0.82 – $73.00
- Volume
- $2.54B
- Avg Volume
- $1.84B
- Shares Outstanding
- 2.6M
- Next Earnings
- Dec 11, 2026
Fundamentals Snapshot
- Annual Revenue
- $23M
- Last Q Revenue
- $2M
- P/E Ratio
- -0.1
- P/S Ratio
- 1.2x
- EPS (TTM)
- $-34.29
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +36.7%
Why Investors Own MEDS
- ✓High-growth profile — revenue up +48.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 25% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
DATAMEDS AI INC
MEDSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$23M▲ +28.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-41.3%▼ −523.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$81M▲ +1221.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$11M▲ +577.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
1.4M▲ +36.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$25M▼ −$645K YoY
StockOtter · stockotter.spaceAbout DATAMEDS AI INC
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100
Analyst Price Target
ⓘAverage Target
$3.59
▼ −1.5% Downside
High Target$4.13
Low Target$2.91
Based on 29 analysts
Latest News & Updates
🚀
Reuters·2h ago
DATAMEDS AI INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Reuters·5h ago
Analysts lift MEDS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
DATAMEDS AI INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.